Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients
Pharmgenomics Pers Med
; 10: 101-106, 2017. tab
Article
in English
| Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1065491
Responsible library:
BR79.1
Localization: BR79.1
ABSTRACT
BACKGROUND:
The effects of genetic variants related to the pharmacodynamic mechanisms of immunosuppressive drugs on their therapeutic efficacy and safety have been poorly explored. This study was performed to investigate the influence of the PPP3CA c.249G>A variant on the clinical outcomes of kidney transplant recipients.PATIENTS ANDMETHODS:
A total of 148 Brazilian patients received tacrolimus (TAC)-based immunosuppressive therapy for 90 days post-kidney transplantation. The PPP3CA rs3730251 (c.249G>A) polymorphism was determined by real-time polymerase chain reaction. Single-nucleotide polymorphism (SNP) data for CYP3A5 rs776746 (CYP3A5*3C; g.6986A>G) were used to eliminate the confounding effects of this variant.
Full text:
Available
Collection:
National databases
/
Brazil
Database:
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Main subject:
Kidney Transplantation
/
Tacrolimus
Type of study:
Risk factors
Language:
English
Journal:
Pharmgenomics Pers Med
Year:
2017
Document type:
Article
Institution/Affiliation country:
Federal University of Sao Paulo/BR
/
Uniformed Services University of the Health Sciences/US
/
University of São Paulo/BR